NIH awards University of Chicago $1.5 million to study novel therapy for multiple sclerosis
September 18, 2013
Researchers from the University of Chicago have been awarded a five-year, $1.5 million grant from the National Institutes of Health (NIH) to develop stimulated dendritic cell-derived exosomes that show remarkable promise as a treatment for multiple sclerosis and other neurological diseases involving loss of myelin, the insulation around nerve fibers.
Exosomes produced in the blood appear to play a causal role in the protective effects of regular exercise and learning, collectively known as "environmental enrichment," on the brain. These exosomes contain specific microRNAs that promote myelination of aging brain as well as brain damaged by multiple sclerosis modeled in animal brain tissues.
Based on this discovery, the Kraig lab is currently exploring the possibility of using cultured dendritic cells to recreate this effect. To do so will open new research opportunities for treatment of disorders that occur with a loss of myelin.
Led by Richard Kraig, MD, PhD, the William D. Mabie Professor in the Neurosciences in the department of Neurology at the University of Chicago, the research project is part of the Extracellular RNA Communication program, which aims to better understand extracellular RNA. This new initiative is supported by the NIH Common Fund, which funds high-impact, trans-NIH projects that have the potential to dramatically affect biomedical research over the next decade.
The Kraig project focuses on exosomes -- small lipid vesicles that carry protein, RNA, and importantly, non-coding, extracellular microRNA, which are thought to enable cell-to-cell communication throughout the body.
Kraig and his team, which includes Aya Pusic and Kae Pusic, PhD, discovered that dendritic cells, professional antigen presenting cells of the immune system, can be stimulated by factors released during environmental enrichment to produce exosomes containing microRNAs that improve brain health.
When applied to cultured brain tissue or administered nasally to live animals, these dendritic cell-derived exosomes significantly increased baseline levels of myelin -- the protective sheath around neurons, which is damaged in multiple sclerosis. Importantly, exosome administration also improved the recovery of demyelinated nerve cells, which serve as a model for multiple sclerosis.
"All evidence suggests these exosomes can be crafted into a novel therapy to treat multiple sclerosis," Kraig said. "The NIH Common Fund grant allows us to pursue the development of this promising discovery, while simultaneously characterizing its basic mechanisms."
Dendritic cell-derived exosomes have no known toxic effects, can cross the blood-brain barrier without use of an additional delivery vehicle and are scalable for mass production through laboratory-cultured dendritic cells. These traits make them an extremely promising treatment for multiple sclerosis and many other neurodegenerative diseases that involve loss of myelination, such as traumatic brain injury. They may also be useful in slowing the degradation that occurs with normal aging.
The Kraig lab will investigate the underlying biological mechanisms and functions of the extracellular microRNAs contained in stimulated dendritic cell-derived exosomes. In addition, the team will study a promising link between these exosomes, reduced oxidative stress and increased antioxidant levels seen in treated brains, effects they hope also will lead to potential therapeutics for neurological diseases.
"We believe that we have identified a naturally occurring mechanism by which increased exercise and learning improves brain health through myelination," said Kraig. "Importantly, we have also discovered a way to mimic this nutritive effect through the use of cultured dendritic cell-derived exosomes containing specific microRNAs."
Multiple sclerosis (MS) is a disease in which the body's immune system attacks and destroys the protective covering of the nerves, called the myelin sheath, through a process called demyelination. Over time, the brain, spinal cord and the rest of the body lose the ability to communicate with each other. Many people with MS eventually lose the ability to walk or speak clearly. MS affects about 2.5 million people worldwide, including 400,000 in the United States. Current MS therapies can slow the disease by reducing demyelination, but no treatment exists to restore the lost myelin.
The NIH Common Fund encourages collaboration and supports a series of exceptionally high-impact, trans-NIH programs. Common Fund programs are designed to pursue major opportunities and gaps in biomedical research that no single NIH institute or center could tackle alone, but that the agency as a whole can address to make the biggest impact possible on the progress of medical research.
Additional information about the NIH Common Fund on Extracellular RNA and the funded projects can be found at:
The University of Chicago Medicine
950 E. 61st Street, Third Floor
Chicago, IL 60637
Phone (773) 702-0025 Fax (773) 702-3171